Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer

Thushangi N. Pathiraja, Shweta R. Nayak, Yuanxin Xi, Shiming Jiang, Jason P. Garee, Dean P. Edwards, Adrian V. Lee, Jian Chen, Martin J. Shea, Richard J. Santen, Frank Gannon, Sara Kangaspeska, Jaroslav Jelinek, Jean Pierre J Issa, Jennifer K. Richer, Anthony Elias, Marie McIlroy, Leonie S. Young, Nancy E. Davidson, Rachel Schiff & 2 others Wei Li, Steffi Oesterreich

Research output: Contribution to journalArticle

Abstract

Resistance to aromatase inhibitors (AIs) is a major clinical problem in the treatment of estrogen receptor (ER)-positive breast cancer. In two breast cancer cell line models of AI resistance, we identified widespread DNA hyper- and hypomethylation, with enrichment for promoter hypermethylation of developmental genes. For the homeobox gene HOXC10, methylation occurred in a CpG shore, which overlapped with a functional ER binding site, causing repression of HOXC10 expression. Although short-term blockade of ER signaling caused relief of HOXC10 repression in both cell lines and breast tumors, it also resulted in concurrent recruitment of EZH2 and increased H3K27me3, ultimately transitioning to increased DNA methylation and silencing of HOXC10. Reduced HOXC10 in vitro and in xenografts resulted in decreased apoptosis and caused antiestrogen resistance. Supporting this, we used paired primary and metastatic breast cancer specimens to show that HOXC10 was reduced in tumors that recurred during AI treatment. We propose a model in which estrogen represses apoptotic and growth-inhibitory genes such as HOXC10, contributing to tumor survival, whereas AIs induce these genes to cause apoptosis and therapeutic benefit, but long-term AI treatment results in permanent repression of these genes via methylation and confers resistance. Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance.

Original languageEnglish (US)
Article number229ra41
JournalScience Translational Medicine
Volume6
Issue number229
DOIs
StatePublished - Mar 26 2014
Externally publishedYes

Fingerprint

Aromatase Inhibitors
Epigenomics
Breast Neoplasms
Estrogen Receptors
DNA Methylation
Methylation
Apoptosis
Genes
Developmental Genes
Cell Line
Estrogen Receptor Modulators
Homeobox Genes
Heterografts
Histones
Neoplasms
Estrogens
Binding Sites
DNA
Therapeutics
Growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pathiraja, T. N., Nayak, S. R., Xi, Y., Jiang, S., Garee, J. P., Edwards, D. P., ... Oesterreich, S. (2014). Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine, 6(229), [229ra41]. https://doi.org/10.1126/scitranslmed.3008326

Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. / Pathiraja, Thushangi N.; Nayak, Shweta R.; Xi, Yuanxin; Jiang, Shiming; Garee, Jason P.; Edwards, Dean P.; Lee, Adrian V.; Chen, Jian; Shea, Martin J.; Santen, Richard J.; Gannon, Frank; Kangaspeska, Sara; Jelinek, Jaroslav; Issa, Jean Pierre J; Richer, Jennifer K.; Elias, Anthony; McIlroy, Marie; Young, Leonie S.; Davidson, Nancy E.; Schiff, Rachel; Li, Wei; Oesterreich, Steffi.

In: Science Translational Medicine, Vol. 6, No. 229, 229ra41, 26.03.2014.

Research output: Contribution to journalArticle

Pathiraja, TN, Nayak, SR, Xi, Y, Jiang, S, Garee, JP, Edwards, DP, Lee, AV, Chen, J, Shea, MJ, Santen, RJ, Gannon, F, Kangaspeska, S, Jelinek, J, Issa, JPJ, Richer, JK, Elias, A, McIlroy, M, Young, LS, Davidson, NE, Schiff, R, Li, W & Oesterreich, S 2014, 'Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer', Science Translational Medicine, vol. 6, no. 229, 229ra41. https://doi.org/10.1126/scitranslmed.3008326
Pathiraja TN, Nayak SR, Xi Y, Jiang S, Garee JP, Edwards DP et al. Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Science Translational Medicine. 2014 Mar 26;6(229). 229ra41. https://doi.org/10.1126/scitranslmed.3008326
Pathiraja, Thushangi N. ; Nayak, Shweta R. ; Xi, Yuanxin ; Jiang, Shiming ; Garee, Jason P. ; Edwards, Dean P. ; Lee, Adrian V. ; Chen, Jian ; Shea, Martin J. ; Santen, Richard J. ; Gannon, Frank ; Kangaspeska, Sara ; Jelinek, Jaroslav ; Issa, Jean Pierre J ; Richer, Jennifer K. ; Elias, Anthony ; McIlroy, Marie ; Young, Leonie S. ; Davidson, Nancy E. ; Schiff, Rachel ; Li, Wei ; Oesterreich, Steffi. / Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. In: Science Translational Medicine. 2014 ; Vol. 6, No. 229.
@article{1a5939b4e5be4fa8a357d57c3c069740,
title = "Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer",
abstract = "Resistance to aromatase inhibitors (AIs) is a major clinical problem in the treatment of estrogen receptor (ER)-positive breast cancer. In two breast cancer cell line models of AI resistance, we identified widespread DNA hyper- and hypomethylation, with enrichment for promoter hypermethylation of developmental genes. For the homeobox gene HOXC10, methylation occurred in a CpG shore, which overlapped with a functional ER binding site, causing repression of HOXC10 expression. Although short-term blockade of ER signaling caused relief of HOXC10 repression in both cell lines and breast tumors, it also resulted in concurrent recruitment of EZH2 and increased H3K27me3, ultimately transitioning to increased DNA methylation and silencing of HOXC10. Reduced HOXC10 in vitro and in xenografts resulted in decreased apoptosis and caused antiestrogen resistance. Supporting this, we used paired primary and metastatic breast cancer specimens to show that HOXC10 was reduced in tumors that recurred during AI treatment. We propose a model in which estrogen represses apoptotic and growth-inhibitory genes such as HOXC10, contributing to tumor survival, whereas AIs induce these genes to cause apoptosis and therapeutic benefit, but long-term AI treatment results in permanent repression of these genes via methylation and confers resistance. Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance.",
author = "Pathiraja, {Thushangi N.} and Nayak, {Shweta R.} and Yuanxin Xi and Shiming Jiang and Garee, {Jason P.} and Edwards, {Dean P.} and Lee, {Adrian V.} and Jian Chen and Shea, {Martin J.} and Santen, {Richard J.} and Frank Gannon and Sara Kangaspeska and Jaroslav Jelinek and Issa, {Jean Pierre J} and Richer, {Jennifer K.} and Anthony Elias and Marie McIlroy and Young, {Leonie S.} and Davidson, {Nancy E.} and Rachel Schiff and Wei Li and Steffi Oesterreich",
year = "2014",
month = "3",
day = "26",
doi = "10.1126/scitranslmed.3008326",
language = "English (US)",
volume = "6",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "229",

}

TY - JOUR

T1 - Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer

AU - Pathiraja, Thushangi N.

AU - Nayak, Shweta R.

AU - Xi, Yuanxin

AU - Jiang, Shiming

AU - Garee, Jason P.

AU - Edwards, Dean P.

AU - Lee, Adrian V.

AU - Chen, Jian

AU - Shea, Martin J.

AU - Santen, Richard J.

AU - Gannon, Frank

AU - Kangaspeska, Sara

AU - Jelinek, Jaroslav

AU - Issa, Jean Pierre J

AU - Richer, Jennifer K.

AU - Elias, Anthony

AU - McIlroy, Marie

AU - Young, Leonie S.

AU - Davidson, Nancy E.

AU - Schiff, Rachel

AU - Li, Wei

AU - Oesterreich, Steffi

PY - 2014/3/26

Y1 - 2014/3/26

N2 - Resistance to aromatase inhibitors (AIs) is a major clinical problem in the treatment of estrogen receptor (ER)-positive breast cancer. In two breast cancer cell line models of AI resistance, we identified widespread DNA hyper- and hypomethylation, with enrichment for promoter hypermethylation of developmental genes. For the homeobox gene HOXC10, methylation occurred in a CpG shore, which overlapped with a functional ER binding site, causing repression of HOXC10 expression. Although short-term blockade of ER signaling caused relief of HOXC10 repression in both cell lines and breast tumors, it also resulted in concurrent recruitment of EZH2 and increased H3K27me3, ultimately transitioning to increased DNA methylation and silencing of HOXC10. Reduced HOXC10 in vitro and in xenografts resulted in decreased apoptosis and caused antiestrogen resistance. Supporting this, we used paired primary and metastatic breast cancer specimens to show that HOXC10 was reduced in tumors that recurred during AI treatment. We propose a model in which estrogen represses apoptotic and growth-inhibitory genes such as HOXC10, contributing to tumor survival, whereas AIs induce these genes to cause apoptosis and therapeutic benefit, but long-term AI treatment results in permanent repression of these genes via methylation and confers resistance. Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance.

AB - Resistance to aromatase inhibitors (AIs) is a major clinical problem in the treatment of estrogen receptor (ER)-positive breast cancer. In two breast cancer cell line models of AI resistance, we identified widespread DNA hyper- and hypomethylation, with enrichment for promoter hypermethylation of developmental genes. For the homeobox gene HOXC10, methylation occurred in a CpG shore, which overlapped with a functional ER binding site, causing repression of HOXC10 expression. Although short-term blockade of ER signaling caused relief of HOXC10 repression in both cell lines and breast tumors, it also resulted in concurrent recruitment of EZH2 and increased H3K27me3, ultimately transitioning to increased DNA methylation and silencing of HOXC10. Reduced HOXC10 in vitro and in xenografts resulted in decreased apoptosis and caused antiestrogen resistance. Supporting this, we used paired primary and metastatic breast cancer specimens to show that HOXC10 was reduced in tumors that recurred during AI treatment. We propose a model in which estrogen represses apoptotic and growth-inhibitory genes such as HOXC10, contributing to tumor survival, whereas AIs induce these genes to cause apoptosis and therapeutic benefit, but long-term AI treatment results in permanent repression of these genes via methylation and confers resistance. Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance.

UR - http://www.scopus.com/inward/record.url?scp=84899096068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899096068&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.3008326

DO - 10.1126/scitranslmed.3008326

M3 - Article

VL - 6

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 229

M1 - 229ra41

ER -